Dr. Kassem Faraj and his co-authors at the University of Michigan found 340B was associated with better treatment adherence for more vulnerable prostate cancer patients.

340B Hospitals’ Low-Income Prostate Cancer Patients Had Better Adherence

Although 340B participation did not correlate to the start of costly treatment for men with advanced prostate cancer enrolled in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.